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Methods: Co-and fibrosis-CLPF were preincubated for 6 h with S and incubated for further 24 h with or without 10 ng/ml TGF-b1. These stimulated CLPF were extracted and checked for adhesion, proliferation, and protein amounts of the TGF-b1 signal pathway.
Results: In Co-CLPF TGF-b1 had no significant effect on adhesion and proliferation. S-preincubation did not influence the TGF-b1-mediated effect. In cells from fibrotic mucosa of CD-patients S-preincubation and TGF-b1 exposition led to an inhibition of proliferation and adhesion to different ECMproteins. In Co-CLPF S and TGF-b1 exposure reduced the Smad2-and phosphoSmad2-concentration. Smad3, phosphoSmad3, Smad4, and Smad7 were not influenced significantly. In contrast in fibrosis-CLPF S exposure led to a decreased phosphorylation of Smad3 and could reduce the effects of intracellular TGF-b1 pathway. Conclusion: S exposure reduces proliferation, adhesion and the phosphorylation of Smad3 in CLPF from fibrotic areas and could demonstrate an approach in fibrogenesis. Aim: Crohn's disease is an ongoing disorder whose treatment, at this time, can help control the disease by lowering the number of times a person experiences a recurrence, but there is no cure. Our recent findings indicate that the activation of SGLT-1, present at apical membrane of enterocytes, interacts with inflammatory signalling and suggest a novel role as an immunological player for this transporter, that orchestrates a local and systemic anti-inflammatory and cytoprotective response, following an inflammatory stimulus, such as LPS. The cornerstone of SGLT-1 activation, resides in the ability to induce reduction of systemic pro-inflammatory signals, such as TNF-a, and induction of endogenous IL-10 production by the host's immune cells. Our studies performed in vitro and in vivo show that SGLT-1 activation is able to provide cytoprotective effects on enterocytes. In the present work, we aim to show that activation of SGLT-1 at intestinal epithelial level may be suggested as a new pharmacological approach for treatment of Crohn's disease. Materials and Methods: Immunofluorescence reaction was performed to stain occludin and ZO-1 in Caco-2 monolayers exposed to DSS. For in vivo studies, a chemically-induced mouse model of chronic intestinal inflammation was used. Following oral treatment with D-glucose, transepithelial electrical resistance of isolated mouse colon and colon length were evaluated. Inflammatory cytokines IL-12, TNF-a, IL-17, IFN-g, KC, and anti-inflammatory IL-10 were evaluated by ELISA in plasma and in organotypic cultures of colon. Results: Crohn's disease is characterized by a disrupted intestinal barrier function, manifested by an increase in intestinal epithelial permeability. This barrier dysfunction is correlated with tight junction (TJ) proteins disruption. Our in vitro studies show that D-glucose in the medium of Caco-2 cells leads to protection of TJ proteins (occludin and ZO-1) from DSSinduced degradation. Oral in vivo administration of D-glucose, leads to protection of TJ and restores barrier function in our Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/3/1/S119/2393621 by guest on 08 March 2019
